Full-Time

Field Reimbursement Manager

Rare Neurology, Hematology, & Nephrology

Deadline 9/4/26
Alexion

Alexion

5,001-10,000 employees

Global biopharmaceuticals focusing on rare diseases

No salary listed

United States

In Person

Must reside in Texas; relocation assistance is not provided. Travel is expected 60–75%, including overnight travel up to four nights per week.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
CRM
Word/Pages/Docs
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Alexion

See people who can refer or advise you

Requirements
  • A Bachelor's degree is required.
  • Five to seven years of experience in the healthcare and/or pharmaceutical/biotech industry is required.
  • At least three years of experience working with buy-and-bill and/or specialty pharmacy networks is required.
  • At least three years of field reimbursement experience is required.
  • Understanding of access processes spanning medical and pharmacy benefit design and the prescription-to-infusion/injection process is required.
  • Experience with products requiring prior authorization, including related billing, coding, and in-office support, is required.
  • Experience working through complex reimbursement issues is required.
  • Experience working with billing and medical claims personnel in a healthcare setting is required.
  • Experience working with integrated health systems is required.
  • Excellent verbal, written, interpersonal communication, and presentation skills are required.
  • The ability to educate physicians and other healthcare professionals confidently in an office procedural environment is required.
  • Strong cross-functional collaboration, business planning, rapport-building, and active-listening skills are required.
  • Demonstrated technical aptitude and proficiency with iPad, laptop, Microsoft Word, Excel, PowerPoint, and Outlook are required.
  • A valid driver's license and clean driving record are required.
  • The ability to travel regionally, cover large multi-state territories, travel 60–75%, and travel overnight for up to four nights per week is required.
  • The ability to reside in the assigned territory and travel to assigned targets using a company-provided fleet electric vehicle is required.
Responsibilities
  • Partner with cross-functional partners on account and territory planning, strategy, documentation, and presentation of plans.
  • Serve as the subject matter expert on reimbursement and the regional access landscape, including benefit design, product acquisition, payer policies, coverage criteria, prior authorization, denials, appeals, peer-to-peer processes, and patient access education.
  • Develop and execute strategic account and territory plans that increase customer knowledge of reimbursement and access processes and use data and field insights to prioritize activities and guide call objectives.
  • Collaborate with patient services on individual case-management needs related to healthcare provider education on reimbursement issues.
  • Identify, document, and communicate field insights about payer policy shifts, access barriers, denial trends, operational challenges, and customer education needs.
  • Share insights and coordinate activities with cross-functional partners, including market access, patient services, medical, sales, compliance, and legal teams.
  • Maintain accurate documentation and operational reporting for customer interactions, account plans, healthcare provider office education, and case-related activity in customer relationship management and approved systems.
  • Manage work in alignment with annual priorities, key performance indicators, territory objectives, project priorities, and approved budget parameters.
  • Comply with applicable laws, regulations, company policies, and the company's Code of Ethics and Business Conduct.
  • Travel to work-related meetings and functions, including regional and overnight travel, while performing field-based education and case-support activities.
Desired Qualifications
  • Experience in rare diseases is preferred.
  • Understanding of top regional and national payers within the assigned geography is preferred.
  • Experience launching a specialty pharmaceutical or biologic product or a new product indication is preferred.
  • Neurology, hematology, and/or nephrology experience is preferred.
  • PACS (Prior Authorization Certification Specialist) is preferred.
  • Familiarity with applying artificial intelligence tools and techniques to improve efficiency is preferred.
  • Residing within Texas is preferred.

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ultomiris received FDA priority review June 15, 2026 for IgA nephropathy.
  • Alexion advanced ALXN2220 into phase 3 for ATTR-CM on April 10, 2026.
  • AAN 2026 data highlighted gefurulimab, Koselugo, and Ultomiris across neurology indications.

What critics are saying

  • Epysqli, a Soliris biosimilar, won FDA approval July 22, 2026, crushing legacy margins.
  • Strensiq successor efzimfotase alfa missed the adult primary endpoint in March 2026.
  • Alexion remains exposed to Ultomiris concentration; one setback hits hematology, nephrology, and neurology growth.

What makes Alexion unique

  • Alexion built first-mover complement biology expertise and still leads C5 inhibition.
  • AstraZeneca gives Alexion global scale, capital, and regulatory reach in rare disease.
  • Its portfolio spans Soliris, Ultomiris, Strensiq, Kanuma, and emerging antibody modalities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old